Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Bought by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. grew its position in Caribou Biosciences, Inc. (NASDAQ:CRBU) by 63.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,380 shares of the company’s stock after acquiring an additional 6,768 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Caribou Biosciences were worth $34,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Vanguard Group Inc. boosted its stake in Caribou Biosciences by 3.8% during the 1st quarter. Vanguard Group Inc. now owns 4,110,795 shares of the company’s stock worth $21,129,000 after purchasing an additional 148,751 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Caribou Biosciences by 25.7% during the second quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock worth $4,302,000 after buying an additional 536,162 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Caribou Biosciences in the 2nd quarter valued at about $2,432,000. Bank of New York Mellon Corp raised its stake in Caribou Biosciences by 14.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 308,273 shares of the company’s stock valued at $506,000 after acquiring an additional 38,098 shares during the last quarter. Finally, Bruce & Co. Inc. lifted its position in Caribou Biosciences by 50.0% during the 2nd quarter. Bruce & Co. Inc. now owns 300,000 shares of the company’s stock worth $492,000 after acquiring an additional 100,000 shares during the period. 77.51% of the stock is currently owned by hedge funds and other institutional investors.

Caribou Biosciences Price Performance

Caribou Biosciences stock opened at $1.96 on Friday. The stock’s 50 day moving average price is $1.96 and its 200 day moving average price is $2.35. Caribou Biosciences, Inc. has a 1-year low of $1.50 and a 1-year high of $8.33. The company has a market cap of $177.11 million, a PE ratio of -1.41 and a beta of 2.27.

Caribou Biosciences (NASDAQ:CRBU) last issued its earnings results on Tuesday, August 6th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.04. The company had revenue of $3.46 million for the quarter, compared to analyst estimates of $3.31 million. Caribou Biosciences had a negative net margin of 372.78% and a negative return on equity of 34.76%. On average, equities research analysts anticipate that Caribou Biosciences, Inc. will post -1.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Royal Bank of Canada restated an “outperform” rating and set a $14.00 price target on shares of Caribou Biosciences in a research note on Wednesday, August 7th. HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Caribou Biosciences in a research note on Tuesday, September 3rd. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.25.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.